Atlas Molecular Pharma

What Atlas Molecular Pharma does

Atlas Molecular Pharma is a clinical-stage biopharmaceutical company founded in September 2015 as a spin-off of CIC bioGUNE in Derio (Bizkaia), Spain. The company applies a proprietary NMR-based discovery platform called Chassys™ to identify second-generation allosteric pharmacological chaperones — non-inhibitory ligands designed to stabilize destabilized mutant enzymes and address the root pathology of rare and ultra-rare metabolic and neurodegenerative diseases.

Its pipeline comprises four drug candidates: ATL-001, an oral pharmacological chaperone repurposed from the approved antifungal cyclopirox for congenital erythropoietic porphyria (CEP), currently in Phase I/II trials in the United States following FDA authorization in July 2022; ATL-001b for porphyria cutanea tarda (lead validation); ATL-002 for tyrosinemia type I (hit validation); and ATL-003 for prion disease such as Creutzfeldt-Jakob disease (hit identification). Discovery combines de novo chemistry with a drug-repurposing strategy that leverages compounds already approved by regulatory agencies.

The business model is explicitly asset-light and license-oriented: Atlas conducts discovery and early clinical development through Phase I/II internally, then seeks licensing or partnership transactions with larger pharmaceutical or biotechnology companies for late-stage development, commercialization, and distribution. As of the available data, the company is pre-revenue, has ~11 employees, has raised €3 million in equity funding (Feb 2022, led by Inveready with CDTI and EZTEN), and supplements operations with EU/FEDER and NextGenerationEU grant funding.

Name

Atlas Molecular Pharma

Legal name

ATLAS MOLECULAR PHARMA

Website

https://atlasmolecularpharma.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Atlas Molecular Pharma is a Spain-based, clinical-stage biopharmaceutical company that uses its proprietary Chassys™ NMR platform to discover allosteric pharmacological chaperones for rare and ultra-rare diseases, licensing candidates to larger pharma partners for late-stage development and commercialization.

Ownership category

akta.pro rank

Product category

Rare Disease Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Rare disease therapeutics
• Pharmacological chaperones
• Drug discovery platform
• Biopharmaceutical R&D
• Allosteric modulators

Headquarters

HQ city

Derio

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Licensing Royalties: The company's primary business model is to discover first-in-class innovative therapeutics for rare and ultra-rare diseases and license them to larger pharma/biotech partners who will deliver them to market. Revenue is generated through upfront payments, milestone payments, and royalties from licensing agreements.

Go-to-market motion1 record

Marketing channels4 records

Core offering

Atlas Molecular Pharma is a clinical-stage biopharmaceutical company that discovers first-in-class pharmacological chaperone therapeutics for rare and ultra-rare diseases. Using its proprietary Chassys™ NMR-based drug discovery platform, the company identifies and develops allosteric chaperone drug candidates (ATL-001, ATL-001b, ATL-002, ATL-003) and licenses them to larger pharmaceutical partners for late-stage development and commercialization.

Product overview

Atlas Molecular Pharma is a spin-off from CIC bioGUNE (founded in September 2015 in Biscay, Spain) developing first-in-class pharmacological chaperone therapeutics for rare and ultra-rare diseases. The company's portfolio includes four drug candidates: ATL-001 (for congenital erythropoietic porphyria, in Phase I/II), ATL-001b (for porphyria cutanea tarda, lead validation), ATL-002 (for tyrosinemia type I, hit validation), and ATL-003 (for prion disease, hit identification). These therapeutics are discovered and developed using the proprietary Chassys™ NMR-based technology platform, which generates allosteric pharmacological chaperones to stabilize destabilized proteins underlying rare disease pathologies.

Differentiator

Problem solved

Functional benefit

Products and services

• ATL-001 A pharmacological chaperone therapeutic candidate targeting congenital erythropoietic porphyria (CEP), an ultra-rare autosomal recessive disorder caused by deficiency in uroporphyrinogen III synthase enzyme, currently in Phase I/II clinical trials in the United States.
• ATL-001b A pharmacological chaperone therapeutic candidate for porphyria cutanea tarda (PCT), the most common form of porphyria, targeting uroporphyrinogen decarboxylase deficiency to improve heme homeostasis, currently at lead validation stage.
• ATL-002 A pharmacological chaperone therapeutic candidate for tyrosinemia type I, an inborn error of metabolism caused by fumarylacetoacetate hydrolase (FAH) gene mutations, currently at hit validation stage.
• ATL-003 A pharmacological chaperone therapeutic candidate for prion diseases (e.g., Creutzfeldt-Jakob disease), targeting the abnormal accumulation of misfolded prion proteins in the brain, currently at hit identification stage.

Quantifiable outcome

• Identified cyclopirox as drug candidate demonstrating activity against congenital erythropoietic porphyria through biochemical and biophysical experiments with thousands of compounds
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• CIC bioGUNEcoreStrategic or Co-development PartnerAtlas Molecular Pharma was founded as a spin-off company from CIC bioGUNE (Centre for Co-operative Research in Biosciences). The company maintains collaborative research relationships, including work with Dr. Óscar Millet's Precision Medicine and Metabolism Laboratory and Dr. Joaquín Castilla's Prion Laboratory.
• Dr. Óscar Millet Research GroupcoreStrategic or Co-development PartnerResearch collaboration with Dr. Óscar Millet's group at CIC bioGUNE led the identification of cyclopirox as a drug candidate for congenital erythropoietic porphyria through biochemical and biophysical experiments.
• Dr. Joaquín Castilla Research GroupcoreStrategic or Co-development PartnerCollaboration with Dr. Joaquín Castilla's group at CIC bioGUNE's Prion Laboratory contributed to the research on congenital erythropoietic porphyria and drug development strategy.

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Gain Therapeutics: Gain Therapeutics is a clinical-stage biotechnology company that uses computational supercomputing and an allosteric drug discovery platform to develop small-molecule pharmacological chaperones for rare diseases — the same core modality and target indication type as Atlas Molecular Pharma's Chassys™ platform.
• Amicus Therapeutics: Amicus Therapeutics is a global rare disease biotechnology company whose lead commercial product (Galafold/migalastat) is itself a pharmacological chaperone for Fabry disease. It is the most established commercial proof-point for the chaperone modality Atlas is pursuing.
• Minoryx Therapeutics: Minoryx is a clinical-stage biotech developing small-molecule therapies for rare CNS and metabolic diseases (including X-linked adrenoleukodystrophy), with a comparable asset profile: a small European team, repurposing/small-molecule approach, and out-licensing-ready rare disease pipeline.

Broad incumbents

• BioMarin Pharmaceutical: BioMarin is a leading global rare disease biopharmaceutical company with multiple approved orphan therapies. It is a likely licensing/acquisition counterparty for Atlas's pipeline assets and operates in the same therapeutic categories (rare metabolic disorders).
• Ultragenyx Pharmaceutical: Ultragenyx is a commercial-stage rare disease biopharma with a broad pipeline of therapies for genetic and ultra-rare diseases, including enzyme replacement and small-molecule programs — comparable in target indication space and a potential strategic acquirer or partner.
• Alexion / AstraZeneca Rare Disease: Alexion, now part of AstraZeneca, is a global leader in rare diseases with multiple orphan drug franchises. It operates as a broad incumbent that regularly in-licenses and acquires rare disease assets like those Atlas is developing.
• BridgeBio Pharma: BridgeBio develops and commercializes genetically targeted therapies for rare diseases across multiple subsidiaries. It is comparable in operating model (asset-focused subsidiaries targeting rare genetic conditions) and is a plausible licensing partner for pipeline assets.

Emerging players

• Crinetics Pharmaceuticals: Crinetics is a clinical-stage biopharma developing small-molecule therapies for rare endocrine diseases. It is comparable as a similarly sized rare-disease small-molecule developer with a platform approach, providing a relevant valuation and pipeline benchmark.
• Pharvaris: Pharvaris is a clinical-stage biopharma developing small-molecule therapies for rare diseases (hereditary angioedema). It shares Atlas's small-molecule, asset-focused, licensing-ready approach to rare diseases and a comparable size and stage profile.
• Reneo Pharmaceuticals: Reneo is a clinical-stage rare disease biotech developing therapies for rare mitochondrial diseases. Its small-molecule, rare-disease focus and clinical-stage profile make it a useful comparator for Atlas in size, stage, and licensing strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/in/susanacastel
• Xx.com/atlasmolecular

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Atlas Molecular Pharma